OncLive |
Expert Details Developments in MPN Paradigm
OncLive Before that, low-dose aspirin and phlebotomy has been and still is the mainstay treatment. For those who need something further, hydroxyurea is [indicated in the] first-line [setting]. There are other options. Ruxolitinib is now FDA approved as a ... |
from phlebotomy - Google News http://bit.ly/2jiROel
No comments:
Post a Comment